Iprasol Refil - 20mcg + 100mcg/puff

Inhalation

Pack Size : 1 Inhaler x 1 Packet

Generics : Salbutamol + Ipratropium (Inhaler)

Manufacturer : Beximco Pharmaceuticals Ltd.

Best Price * TK 230.00

* Delivery will be done in Dhaka city only.

Alternative Product

Inhalation Ipralin HFA Inhalation - 200 Puff Aristopharma Limited

Tk 250.00

More Information About - Iprasol Refil - 20mcg + 100mcg/puff

Description

Generic Name

Ipratropium Bromide + Salbutamol

Precaution

May cause paradoxical bronchospasm. Caution when used in patients who are sensitive to sympathomimetic agents. Caution when used in patients with CV disease as beta-agonists may increase BP, heart rate and risk of arrhythmias. Monitor blood glucose in diabetics. Monitor serum potassium levels especially in patients who are on concurrent treatment with xanthine derivatives, steroids or diuretics. Caution when used in patients with narrow angle glaucoma, hyperthyroidism, prostatic hyperplasia, bladder neck obstruction, seizure disorders, renal or hepatic impairment. Safety and efficacy have not been established in children <12 yr. Increased risk of GI motility disturbance in patients with cystic fibrosis. Pregnancy and lactation. Lactation: Unknown whether drug is excreted in breast milk

Indication

Chronic obstructive pulmonary disease, Asthma

Contra Indication

The combination of Salbutamol & Ipratropium Bromide is contraindicated in patients with hypertrophic obstructive cardiomyopathy and tachyarrhythmia and in patients with a history of hypersensitivity to atropine or its derivatives, or to any other component of the product.

Dose

N/A

Side Effect

>10% Bronchitis (2-12%) 1-10% Upper respiratory tract infection (1-10%),Lung disease (6%),Headache (3-6%),Dyspnea (2-5%),Nasopharyngitis (4%),Cough (3-4%),Pharyngitis (2-4%),Pain (1-3%),Chest pain (2.6%),Sinusitis (2.3%),Nausea (1-2%),Diarrhea (1.8%),Urinary tract infection (1.6%),Influenza (1.4%),Leg cramps (1.4%),Nausea (1.4%),Pneumonia (1.4%),Rhinitis (1.1%) <1% Allergic-type reactions, such as skin reactions (eg, rash, pruritus, urticaria [including giant urticaria]), angioedema (eg, of tongue, lips, face), laryngospasm, and anaphylaxis Angina,Arrhythmia,Arthralgia,Dizziness,Dry mouth,Dyspepsia,Dysphonia,Edema,Fatigue,Hypertension,Insomnia,Nervousness,Palpitation,Paresthesia,Tachycardia,Tremor,Vomiting Potentially Fatal: Anaphylactic reactions such as angioedema of tongue, lips or face and laryngospasm.

Pregnancy Category

Name : C

Description

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Mode of Action

Ipratropium bromide is an anticholinergic agent that inhibits vagally-mediated reflexes by antagonising the action of acetylcholine. It prevents the increases in intracellular concentration of cyclic guanosine monophosphate (cyclic GMP) which are brought about by interaction of acetylcholine with the muscarinic receptors on bronchial smooth muscle. Salbutamol is a direct-acting beta 2-adrenergic agent. It acts on the airway smooth muscle resulting in bronchodilation.

Interaction

May have additive anticholinergic effects when used with psychotropics; may decrease effect of propranolol. Increased CV effects (tachycardia, palpitations) when used with MAOIs, TCAs and amphetamines.

Pregnancy Category Note

Pregnancy category: C Lactation: Unknown whether drug is excreted in breast milk

Adult Dose

Inhalation Chronic obstructive pulmonary disease Adult: Inhalation: 100 mcg/20 mcg (1 actuation of metered-dose inhaler) q6hr; not to exceed 6 actuations/day Nebulizer solution: Initially, 3 ml every 6 hr. Max: 3 ml every 4 hr. One ampoule as required for the relief of symptoms or as directed. Up to three to four ampoules daily.

Child Dose

Safety and efficacy not established

Renal Dose

N/A

Administration

N/A

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.